Specialist in nuclear medicine and Head of the Department of Nuclear Medicine at Vienna General Hospital (AKH).
Dr. Marcus Hacker is a specialist in nuclear medicine with extensive clinical and scientific experience in molecular imaging using PET/CT diagnostics, as well as in radionuclide therapy for oncological diseases, particularly prostate cancer.
Since 2013, he has been Professor of Nuclear Medicine at the Medical University of Vienna, where he heads the University Clinic of Nuclear Medicine at Vienna General Hospital (AKH). In this role, he combines clinical excellence with university teaching and internationally recognised research.
A key focus of his work is the further development and clinical application of modern PET tracers and radiopharmaceuticals for oncological therapy, including PSMA-based procedures, as well as interdisciplinary collaboration with urology, oncology and other medical specialties. Dr. Hacker is the author and co-author of more than 500 scientific publications in renowned international journals and is regularly involved in national and international research projects.
At Theranosticum Vienna, Dr. Hacker contributes his many years of university and clinical expertise to precise reporting, medical assessment and evidence-based decision-making. His aim is to provide clear, structured diagnostics as the basis for comprehensible, individually tailored medical therapy recommendations.
Memberships
- Society of Nuclear Medicine and Molecular Imaging (SNMMI)
- European Association of Nuclear Medicine (EANM)
- Society of Nuclear Medicine and Molecular Imaging (SNMMI)
Languages
- German
- English
Professional Background
After completing his medical studies at the Medical University of Graz, Dr. Hacker underwent specialist training in surgery and has since worked at various hospitals in Austria.
Publications
- Einspieler H., Kluge K., Haberl D., et al., Hacker M., Rasul S.
Assessment of PSMA Expression of Healthy Organs in Different Stages of Prostate Cancer Using [¹⁸Ga]Ga-PSMA-11-PET Examinations.
Cancers. 2024;16(8):1514. - K Kluge, H Einspieler, D Haberl, CP Spielvogel, et al., M Hacker
Comparison of discovery rates and prognostic utility of [¹⁸Ga]Ga-PSMA-11 PET/CT and circulating tumor DNA in prostate cancer.
European Journal of Nuclear Medicine and Molecular Imaging, 2024. - CP Spielvogel, J Ning, K Kluge, et al., M Hacker
Preoperative detection of extraprostatic tumor extension in patients with primary prostate cancer utilizing [¹⁸Ga]Ga-PSMA-11 PET/MRI.
Insights into Imaging, 2024. - K Kluge, H Einspieler, D Haberl, et al., M Hacker
Examining the Relationship and Prognostic Significance of Cell-Free DNA Levels and PSMA-Positive Tumor Volume in Men with Prostate Cancer: A Retrospective-Prospective [¹⁸Ga]Ga-PSMA-11 PET/CT Study.
Journal of Nuclear Medicine, 2024. - Sundar LKS, Hacker M., Beyer T., et al.
Towards holistic assessment of human physiology: Fully automated total-body PET/CT normative database.
European Journal of Nuclear Medicine and Molecular Imaging, 2023. - Hong Z., Spielvogel CP., Li X., et al., Hacker M.
Enhanced diagnostic and prognostic assessment using advanced PET imaging approaches.
European Journal of Nuclear Medicine and Molecular Imaging, 2025.
“Many patients come to us with uncertainty. It is important to me that findings are not only medically accurate but also provide clear guidance. Good diagnostics should help patients better understand their situation and see the next steps more clearly.”
Dr. Marcus Hacker
We take time for what matters - your care
If you have questions or would like to schedule an appointment, we are here for you.
In a personal consultation, we discuss your concerns in a calm setting and outline the next steps together.
Our team will get back to you promptly and support you competently and reliably - from the first contact through to your therapy appointment.
